Journal
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Volume 17, Issue 3-4, Pages 217-228Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10911-012-9265-1
Keywords
Apoptosis; IAPs; Smac; Small-molecule drugs
Categories
Funding
- Breast Cancer Research Foundation
- Prostate Cancer Foundation
- Department of Defense Prostate Cancer Program [W81XWH-04-1-0213]
- Ascenta Therapeutics
- National Cancer Institute, NIH [5R01CA109025, 5R01CA127551]
Ask authors/readers for more resources
Apoptosis resistance is a hallmark of human cancer. Research in the last two decades has identified key regulators of apoptosis, including inhibitor of apoptosis proteins (IAPs). These critical apoptosis regulators have been targeted for the development of new cancer therapeutics. In this article, we will discuss three members of IAP proteins, namely XIAP, cIAP1 and cIAP2, as cancer therapeutic targets and the progress made in developing new cancer therapeutic agents to target these IAP proteins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
